CoBioRes’ scientists have optimized chemotherapy treatments that are aimed at reducing systemic toxicity while preserving high antitumor efficacy.
This is based on CoBioRes’ tetra-drug technology in which a tetrapeptide sequence is linked to a cytotoxic payload, rendering the compound cell impermeable and thus inactive.
In the tumor microenvironment, the compound is activated by a unique enzymatically driven mechanism, allowing for a spatially regulated 2-step activation (figure 1). The first step of activation happens extracellularly, and is mediated by an endopeptidase that is upregulated and secreted only in the tumor microenvironment, leading to the formation of the dipeptide-coupled chemotherapy. This intermediate is then taken up by the tumor cells, where it is further activated by a second enzymatic cleavage by a specific set of exopeptidases, finally releasing the active chemotherapeutic in the tumor cell.
Figure 1: Mechanism of action of the tetra-technology.
CBR-T01, CoBioRes’ lead candidate, is doxorubicin-based, and has shown superior safety and efficacy in several preclinical animal models. It is currently being tested in the final regulatory studies, and it is expected to enter the clinic by end 2021.
In the meantime, CoBioRes is actively working on several other compounds, based on its tetra-technology. This with different payloads and in different indications.
Figure 2: CoBioRes pipeline
Overall, the Tetra-drug platform allows conversion of highly potent/intolerable cancer drugs into safe products with superior efficacy.
This leads to highly specific tumor-targeted compounds with an increased safety profile and a very broad applicability.